Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity-Reference-Cited by-同舟云学术

Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity

Published:2022 Issue:6 Volume:13 Page:711-725
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Boudreau Matthew W.¹^ORCID,Hergenrother Paul J.¹^ORCID

Affiliation:

1. Dept. of Chemistry, Carl R. Woese Institute for Genomic Biology, Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

Abstract

Some compounds possessing the 3-(4-hydroxyphenyl)indoline-2-one pharmacophore (ErSO, ErSO-DFP, and others) have significant antitumor activity in preclinical models and induce cancer cell death via an intriguing mode-of-action.

Funder

National Cancer Institute

National Institute of General Medical Sciences

University of Illinois at Urbana-Champaign

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MD/D2MD00110A

Reference128 articles.

1. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

2. Discovering new biology with drug-resistance alleles

3. The Rise of Molecular Glues

4. Monomeric Targeted Protein Degraders

5. PROTAC targeted protein degraders: the past is prologue

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets;Pharmacology & Therapeutics;2024-02